• Profile
Close

Efficacy of Hemospray (TC-325) in the treatment of gastrointestinal bleeding: An updated systematic review and meta-analysis

Journal of Clinical Gastroenterology Jun 15, 2021

Chahal D, Sidhu H, Zhao B, et al. - Researchers aimed at retrieving data regarding the use pattern of hemospray (TC-325) in gastrointestinal bleeding. In addition , they investigated their efficacy, complications, and impact on clinical outcomes. Electronic search from relevant databases yielded 27 articles for inclusion in this analysis (n = 1,916). Findings revealed pooled hemostasis in 94.5%; pooled rebleed rate of 9.9% within 3 days, and 17.6% within 30 days. Pooled repeat Hemospray use was reported in 13.6%. Radiology guided embolization was necessitated in 3.3% and surgery at a rate of 4.7%. Overall findings suggest an increased rate of immediate hemostasis in correlation with adding Hemospray to conventional therapy but there was no reduction in rebleeding or mortality. As such, the use of Hemospray will likely be limited to clinical situations necessitating urgent, but temporary, hemostasis to bridge to more definitive therapy.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay